Novel Platinum-Based Drug （HJ-550 ）

A first-in-class targeted bivalent platinum drug exhibits overall superior efficacy over first-line standard-of-care treatments as monotherapy and in combination, holding potential to transform first-line tumor therapeutic strategies.